Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Advanced Biliary Tract Carcinoma
NCT02053376Phase 2Completed
- Start
- Jan 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in biliary tract carcinoma (BTC), cholangiocarcinoma (CCA). Started Jan 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
biliary tract carcinoma (BTC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02053376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02053376.